Coherus BioSciences (CHRS) Reports Q3 Loss Per Share of $1.86
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.25 -3.85%
Revenue Growth %: +37.8%
Financial Fact:
Basic net income/(loss) per share: 0.15
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +37.8%
Financial Fact:
Basic net income/(loss) per share: 0.15
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.86), versus ($1.79) reported last year. Revenue for the quarter came in at $7.2 million, versus $16.1 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Coherus Oncology hires Oppenheimer to sell biosimilar assets
- General Mills (GIS) Tops Q1 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
